Invion Limited

IVX

AU000000IVX4

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 07:10:53 31/05/2024 BST			5-day change	1st Jan Change
0.005 ^AUD	+25.00%		-.--%	-.--%

05-08	Invion Partners with Hanlim Pharma for Glioblastoma Treatment	MT
03-05	Invion's Anti-Cancer Drug Logs Postive Preclinical Trial Results	MT

Invion Limited Announces the Cessation of Greg Collier as Director

November 04, 2019 at 01:18 am

Invion Limited announced the cessation of Greg Collier as director effective 4 November 2019.

Latest news about Invion Limited

Invion Partners with Hanlim Pharma for Glioblastoma Treatment	05-08	MT
Invion's Anti-Cancer Drug Logs Postive Preclinical Trial Results	03-05	MT
Invion Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-27	CI
Invion Signs Collaboration Agreement with Dr. I&B Co for HPV Treatment; Shares Up 25%	02-23	MT
Invion Nears Clinical Trial of Cancer Photodynamic Therapy with Drug Substance Production	11-21	MT
Invion Grants RMW Cho Group Right to Distribute Cancer Treatment Products in South Korea	26/09/23	MT
Invion Limited Reports Earnings Results for the Full Year Ended June 30, 2023	31/08/23	CI
Invion Launches New Interactive Investor Hub	11/04/23	MT
Invion Limited agreed to acquire Next Generation Photodynamic Therapy of RMW Cho Group Limited.	05/04/23	CI
Invion Limited Reports Earnings Results for the Half Year Ended December 31, 2022	22/02/23	CI
Invion Expanding Photosoft Technology Rights to US, Canada, Hong Kong	08/02/23	MT
Invion Limited Announces Vitro Test Results on Photosoft	26/10/22	CI
Invion Limited Announces the Positive Screening Results from in Vitro Studies of PhotosoftTM on the Inhibition of the Dengue Virus	24/10/22	CI
Invion Validates Efficacy of Photodynamic Drug Against Anal Cancer	15/09/22	MT
Invion Limited Announces INV043 Effective Against Anal Cancer Squamous Cell Carcinomas in Vitro	15/09/22	CI
Invion Limited Announces PhotosoftTM Shows Activity Against Zika Virus in Preliminary Assays	08/09/22	CI
Invion Limited Reports Earnings Results for the Full Year Ended June 30, 2022	17/08/22	CI
Invion's Cancer Treatment Patent Application Published	09/06/22	MT
Invion Limited Announces International Patent to Extend IP Protection for Photosoft	08/06/22	CI
Invion Limited Reports Earnings Results for the Half Year Ended December 31, 2021	22/02/22	CI
Invion Limited Announces Company Secretary Changes	29/10/21	CI
Invion's Cancer Drug Regresses Tumor, Triggers Immune Response in Animal Study; Shares Surge 131%	28/10/21	MT
Invion Limited Announces INV043 Shown to Completely Regress TNBC Tumours and Trigger Protective Immunity	27/10/21	CI
Invion Limited Reports Earnings Results for the Full Year Ended June 30, 2021	05/08/21	CI
Invion Limited Auditor Raises 'Going Concern' Doubt	03/08/21	CI

Invion Limited is an Australia-based life science company. The Company is engaged in the research and development of Photosoft technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. The Company is developing Photosoft technology as a Photodynamic Therapy (PDT). PDT uses non-toxic photosensitizers and light to selectively kill cancer cells and promote an anti-cancer immune response. PDT also offers an alternative treatment option aimed at achieving complete tumor regression and long-lasting remission. PDT has also demonstrated broad-spectrum activity across multiple infectious diseases, including bacteria, fungi and viruses. It holds the Australia and New Zealand license rights and distribution rights to Hong Kong and the rest of Asia Pacific, excluding China, Macau, Taiwan and Japan, to the Photosoft technology for all cancer indications. The Companyâs wholly owned subsidiary is Epitech Dermal Science Pty Ltd.

Sector

Biotechnology & Medical Research

Calendar

28/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
INVION LIMITED	-.--%	21.33M
MODERNA, INC.	+43.36%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
BIO-TECHNE CORPORATION	+0.04%	12.16B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B